Testing haplo transplant for older adults with leukemia or MDS
Part of Blood & lymphatic clinical trials.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 69 years old
- You have acute leukemia or MDS (a blood/marrow condition)
- Your doctors say you could get an allogeneic stem cell transplant (from another person)
- You do not have a fully matched donor, but you do have a half-matched (“haplo”) donor option
- You can and agree to sign the informed consent
- No severe active infection and you are able to complete the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a conditioning regimen that is adjusted by age for people with low- or intermediate-risk myelodysplastic syndromes (MDS) who are receiving a half-matched (haploidentical) stem cell transplant from a family donor. The goal is to see if an age-stratified approach can improve outcomes.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This study tests a way to lower the chance of graft-versus-host disease (a common side effect of stem cell transplants) by removing certain immune cells from the donor's stem cells before they are given to you. It is for older patients with acute leukemia or MDS who are getting a transplant.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a special preparation (conditioning) regimen for patients 55 or older with acute myeloid leukemia (AML) who are in first remission and receiving a half-matched (haploidentical) stem cell transplant. It aims to make the transplant safer and more effective for this age group.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.